

## **Disclosure of Transfers of value to HCPs/HCOs**

### **2022 Self-Certification**

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Angelini Pharma works, provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle, pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its members, such as Farindustria, and TITCK (Turkey Pharmaceuticals and medical device agency) have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members, along with TITCK, are fully committed to implement and apply the highest ethical standards.

Except in countries where disclosure is prescribed by laws, Angelini Pharma<sup>1</sup> hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2021 have been reported in application of the EFPIA Disclosure Code and TITCK Code of Ethics following the key principles listed below:

#### **Disclosure quality**

Angelini Pharma certifies that:

- its disclosures are made in each country where it operates;
- its disclosure includes direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA and TITCK;
- its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

#### **Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code and TITCK Code of Ethics's requirements and applicable codes.**

Angelini Pharma certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code and TITCK Code of Ethics;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code and TITCK Code of Ethics).

**Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons.**

Angelini Pharma certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code and in the TITCK Code of Ethics);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

### Ensuring compliance with Data Privacy Obligations

Angelini Pharma certifies that the collection, processing and disclosure of transfers of value have been made in accordance with Data Privacy obligations.

Date: June 28<sup>th</sup>, 2022

Name of signatory: PIERLUIGI ANTONELLI

Position in the Company: CHIEF EXECUTIVE OFFICER

Signature: 

---

<sup>i</sup> Angelini Pharma is intended as headquarter and its affiliates as per 2021 organization, including Arvelle Therapeutics, acquired in February 2021.